Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies

Figure 1 A common mechanism by which immune checkpoint inhibitors exert their effects involves activation of effector T cells by inhibition of programmed death 1, programmed death-ligand 1, and cytotoxic T-lymphocyte antigen 4. ICI: Immune checkpoint inhibitor; PD-1: Programmed death 1; PD-L1: Programmed death-ligand 1; CTLA-4: Cytotoxic T-lymphocyte antigen 4; irAEs: Immune-related adverse events.